All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

benzbromarone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
antiarrhythmics	318	3562-84-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: benzbromarone benzbromaron azubromaron	Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout. Molecular weight: 424.09 Formula: C17H12Br2O3 CLOGP: 5.98 LIPINSKI: 1 HAC: 3 HDO: 1 TPSA: 50.44 ALOGS: -4.51 ROTB: 3

Drug dosage:

Dose	Unit	Route
0.10	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Hosey CM, Chan R, Benet LZ
S (Water solubility)	0.01 mg/mL	Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	3.471		Moderate	0.77
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.684		Moderate	0.77
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	37.068	10^-6 cm/s	Moderate	0.77
dh-clint	Dog hepatocyte intrinsic clearance	13.740	uL/min/10^6 cells	Moderate	0.77
dppb	Dog plasma protein binding (% unbound)	0.140	%	Moderate	0.77
fcs-ppb	Fetal calf serum protein binding (% unbound)	0.240	%	Moderate	0.77
herg	hERG pIC50	4.700	pIC50	Moderate	0.77
hh-clint	Human hepatocyte intrinsic clearance	20.417	uL/min/10^6 cells	Moderate	0.77
hlm-clint	Human liver microsomal intrinsic clearance	101.158	uL/min/mg protein	Moderate	0.77
hppb	Human plasma protein binding (% unbound)	1.150	%	Moderate	0.77
kinase-safety-class	ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK2,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,KDR,KIT,MAP2K6,MAP3K1,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK1,MAPK10,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MELK,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM1,PIM2,PIM3,PRKAA1,PRKCD,PRKCZ,PRKDC,SIK2,SIK3,STK10,STK33,SYK,TEK,TGFBR1,TTK,UHMK1,ULK1,ULK2,ZAP70	79
kinase-selectivity-class	ACVR2A,ACVR2B,ALK,AURKC,AXL,BRAF,CAMK2D,CDK4,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT4,GRK2,GSK3A,MAP2K3,MAP2K6,MAPK1,MAPK12,MAPK7,MAPK8,MARK4,PIK3CD,PRKDC,RIPK1,SIK2,SIK3,STK10,STK33,SYK,TEK,TGFBR1,TTK,TYRO3,ULK1	37
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	5.929		Moderate	0.77
mh-clint	Mouse hepatocyte intrinsic clearance	20.989		Moderate	0.77
mppb	Mouse plasma protein binding (% unbound)	0.190		Moderate	0.77
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	1.932		Moderate	0.77
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pld-class	Phospholipidosis risk class (1 = positive, 0 = negative)	1		High	1
pppb	Pig plasma protein binding (% unbound)	0.130	%	Moderate	0.77
rh-clint	Rat hepatocyte intrinsic clearance	55.719	uL/min/10^6 cells	Moderate	0.77
rh-fuinc	Rat hepatocyte fraction unbound in incubation	3.210	%	Moderate	0.77
rppb	Rat plasma protein binding (% unbound)	0.260	%	Moderate	0.77
solubility-dd	Solubility at pH 7.4 in DMSO	157.398	uM	Moderate	0.77

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Renal impairment	46.63	26.79	33	1243	110195	42509864
Hepatic function abnormal	32.91	26.79	20	1256	51547	42568512
Interstitial lung disease	29.72	26.79	22	1254	78440	42541619

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Renal impairment	85.49	30.49	47	1729	188398	110399125
Hepatic function abnormal	48.05	30.49	25	1751	89270	110498253
Interstitial lung disease	32.95	30.49	23	1753	139311	110448212

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	M04AB03	MUSCULO-SKELETAL SYSTEM ANTIGOUT PREPARATIONS ANTIGOUT PREPARATIONS Preparations increasing uric acid excretion
CHEBI has role	CHEBI:35674	antihypertensive agent
CHEBI has role	CHEBI:35841	uricosuric drug
CHEBI has role	CHEBI:35845	gout suppressant
MeSH PA	D006074	Gout Suppressants
MeSH PA	D014528	Uricosuric Agents
MeSH PA	D018501	Antirheumatic Agents

Related Drugs by ATC class:

M04AB Preparations increasing uric acid excretion 5 drugs

dotinuradisobromindionelesinuradprobenecidsulfinpyrazone

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hyperuricemia	indication	35885006	DOID:1920
Gout	indication	90560007	DOID:13189

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.91	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Solute carrier family 22 member 12	Transporter	Q96S37	S22AC_HUMAN	INHIBITOR	IC50	7.59		CHEMBL	SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	5.94		DRUG MATRIX
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	5.53		DRUG MATRIX
Transthyretin	Secreted	P02766	TTHY_HUMAN		Kd	7.82		CHEMBL
Multidrug resistance-associated protein 1	Transporter	P33527	MRP1_HUMAN		Ki	6.72		CHEMBL
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		IC50	6.70		CHEMBL
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	7.80		DRUG MATRIX
Aldo-keto reductase family 1 member C1	Enzyme	Q04828	AK1C1_HUMAN		IC50	7.32		CHEMBL
Tyrosine-protein phosphatase non-receptor type 1	Enzyme	P18031	PTN1_HUMAN		IC50	4.27		CHEMBL
cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Enzyme	P27815	PDE4A_HUMAN		IC50	5.98		DRUG MATRIX
Solute carrier family 22 member 6	Transporter	Q4U2R8	S22A6_HUMAN		IC50	5.67		CHEMBL
cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Enzyme	Q08499	PDE4D_HUMAN		IC50	5.68		CHEMBL
Thyroid hormone receptor beta	Nuclear hormone receptor	P10828	THB_HUMAN		Kd	5.05		CHEMBL
Mitogen-activated protein kinase 14	Kinase	Q16539	MK14_HUMAN		IC50	5.91		DRUG MATRIX
Mitogen-activated protein kinase 1	Kinase	P28482	MK01_HUMAN		IC50	5.71		DRUG MATRIX
Eyes absent homolog 2	Enzyme	O00167	EYA2_HUMAN		IC50	4.99		CHEMBL
Eyes absent homolog 3	Enzyme	Q99504	EYA3_HUMAN		IC50	5.08		CHEMBL
Piezo-type mechanosensitive ion channel component 1	Ion channel	Q92508	PIEZ1_HUMAN	INHIBITOR	IC50	5.40		IUPHAR
Bile acid receptor	Nuclear hormone receptor	Q96RI1	NR1H4_HUMAN		EC50	4.61		CHEMBL
M1-family alanyl aminopeptidase	Enzyme		Q8IEK1_PLAF7		IC50	4.20		CHEMBL
Envelope glycoprotein gp160	Viral envelope protein		Q75760_9HIV1		IC50	4.89		CHEMBL
Polymerase acidic protein	Enzyme		PA_I34A1		Kd	4.32		CHEMBL
Eyes absent homolog 3	Enzyme		EYA3_MOUSE		IC50	4.96		CHEMBL
Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120	Viral envelope protein		Q6QLK5_9HIV1		IC50	4.89		CHEMBL
Inosine-5'-monophosphate dehydrogenase	Enzyme		Q9HXM5_PSEAE		IC50	4.26		CHEMBL

External reference:

ID	Source
N0000166974	NUI
D01056	KEGG_DRUG
1385	RXNORM
C0005035	UMLSCUI
CHEBI:3023	CHEBI
R75	PDB_CHEM_ID
CHEMBL388590	ChEMBL_ID
D001553	MESH_DESCRIPTOR_UI
DB12319	DRUGBANK_ID
2333	PUBCHEM_CID
14007	IUPHAR_LIGAND_ID
1427	INN_ID
4POG0RL69O	UNII
005311	NDDF
698025001	SNOMEDCT_US
703372005	SNOMEDCT_US
4POG0RL69O	INXIGHT DRUGS

Pharmaceutical products:

None